Experimental biofilm-related Candida infections

Future Microbiology

Volumn 8, Issue 6, 2013, Pages 799-805

  Cirasola, Daniela ^a   Sciota, Rita ^a   Vizzini, Loredana ^a   Ricucci, Valentina ^a   Morace, Giulia ^a   Borghi, Elisa ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

anidulafungin; biofilm; Candida albicans; experimental infections; Galleria mellonella

Indexed keywords

ANIDULAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; FUNGAL VIRULENCE; GALLERIA MELLONELLA; IN VITRO STUDY; LARVA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; LARVA; LEPIDOPTERA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

CANDIDA; CANDIDA ALBICANS; GALLERIA MELLONELLA; LEPIDOPTERA;

EID: 84878312842     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.36     Document Type: Article

References (31)

1. Vincent J-L, Rello J, Marshal J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302, 2323-2329 (2009
2. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of stay and cost attributable to candidaemia. J. Infect. 59, 360-365 (2009
3. Kett DH, Azoulay E, Echeverria PM, Vincent J-L; Extended Prevalence of Infection in the ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 39, 665-670 (2011
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004 (Pubitemid 39050477)
5. Morace G, Borghi E, Iatta R, et al. Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients. BMC Infect. Dis. 11, 130 (2011
6. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob. Agents Chemother. 55, 561-566 (2011
7. Zirkel J, Klinker H, Kuhn A, et al. Epidemiology of Candida bloodstream infections in patients with hematological malignancies or solid tumors. Med. Mycol. 50, 50-55 (2012
8. Seneviratne CJ, Jin L, Samaranayake LP. Biofilm lifestyle of Candida: a mini review. Oral Dis. 14, 582-590 (2008
9. Nett J, Lincoln L, Marchillo K, et al. Putative role of b-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51, 510-520 (2007 (Pubitemid 46185268)
10. Tobudic S, Kratzer C, Lassnig A, Presteri E. Antifungal susceptibility of Candida albicans biofilms. Mycoses 55, 199-204 (2012
11. Morace G, Borghi E, Iatta R, Montagna MT. Anidulafungin, a new echinocandin in vitro activity. Drugs 69(Suppl. 1), 91-94 (2009
12. Ferreira JAG, Carr JH, Starling CEF, de Resende MA, Donlan RM. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob. Agents Chemother. 53, 4377-4384 (2009
13. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46, 1773-1780 (2002 (Pubitemid 34535196)
14. Shuford JA, Piper KE, Steckelberg JM, Patel R. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn. Microbiol. Infect Dis. 57, 277-281 (2007 (Pubitemid 46330658)
15. Hinske LC, Weis F, Heyn J, Hinske P, Beiras-Fernandez A. The role of micafungin and anidulafungin in the treatment of systemic fungal infections: applications and patents for two novel echinocandins. Recent Pat. Antiinfect. Drug. Discov. 7, 1-7 (2012
16. Bernhardt H, Knoke M, Bernhardt J. Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation. Mycoses 54, e821-e827 (2011
17. Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. 3, e101 (2007
18. Glittenberg MT, Silas S, MacCallum DM, Gow NAR, Ligoxygakis P. Wild-type Drosophila melanogaster as an alternative model system for investigating the pathogenicity of Candida albicans. Dis. Models Mech. 4, 504-514 (2011
19. Coleman JJ, Muhammed M, Kasperkovitz PV, Vyas JM, Mylonakis E. Fusarium pathogenesis investigated using Galleria mellonella as a heterologous host. Fungal Biol. 115, 1279-1289 (2011
20. Borghi E, Sciota R, Biassoni C, et al. Cell surface hydrophobicity: a predictor of biofilm production in Candida isolates? J. Med. Microbiol. 60, 689-690 (2011
21. Samarayanake LP, Raside JM, MacFarlane TW. Factors affecting the phospholipase activity of Candida species in vitro. Sabouraudia 22, 201-207 (1984
22. Sacristan B, Blanco MT, Galan-Ladero MA, Blanco J, Perez-Giraldo C, Gomez-Garcia AC. Aspertyl proteinase, phospholipase, hamolytic activities and biofilm production of Candida albicans isolated from bronchial aspirates of ICU patients. Med. Mycol. 49, 94-97 (2011
23. Cassone A, De Bernardis F, Mondello F, Ceddia T, Agatensi L. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J. Infect. Dis. 156, 777-783 (1987 (Pubitemid 17157428)
24. Pierce CG, Uppuluri P, Tristan AR, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3, 1494-1500 (2008
25. Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J. Microbiol. Methods 72, 157-165 (2008
26. Junqueira JC, Fuchs BB, Muhammed M, et al. Oral Candida albicans isolates from HIV-positive individuals have similar in vitro biofilm-forming ability and pathogenicity as invasive Candida isolates. BMC Microbiol. 11, 247 (2011
27. Hasan F, Xess I, Wang X, Jain N, Fries BC. Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect. 11, 753-761 (2009
28. Cowen LE, Singh SD, Kohler JR, et al. Harnessing the Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl Acad. Sci. USA 106, 2818-2823 (2009
29. Nett JE, Cain MT, Crawford K, Andes DR. Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J. Clin. Microbiol. 49, 1426-1433 (2011
30. European Committee on Antimicrobial Susceptibility Testing. Antifungal susceptibility testing. www.eucast.org/antifungal-susceptibility-testing-afst
31. Official Journal of the European Union L276/33. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the Protection of Animals Used for Scientific Purposes. http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:007 9:en:PDF